Table 6 Associations between the use of Azathioprine or 6-mercaptopurine and patient and treatment characteristics for patients with Crohn's disease
From: A national survey on the patterns of treatment of inflammatory bowel disease in Canada
Characteristics | % reporting Aza/6 MP | Odds ratio | 95% CI |
|---|---|---|---|
Sex | |||
Male | 23.5 | Referent | |
Female | 23.8 | 1.0 | 0.8 to 1.3 |
Age | |||
16–24 | 45.3 | Referent | |
25–40 | 29.0 | 0.5 | 0.3 to 0.8 |
41–55 | 22.3 | 0.4 | 0.2 to 0.6 |
>55 | 15.0 | 0.2 | 0.1 to 0.4 |
Disease activity | |||
Inactive | 19.2 | Referent | |
Mild | 18.5 | 1.0 | 0.7 to1.3 |
Moderate | 26.6 | 1.5 | 1.1 to 2.1 |
Severe | 38.2 | 2.6 | 1.7 to 3.9 |
Hospitalizations Past 5 Years | |||
None | 17.4 | Referent | |
1 – 2 | 26.1 | 1.7 | 1.3 to 2.2 |
> 2 | 38.8 | 3.0 | 2.2 to 4.1 |
Surgery within the past 2 years | |||
No | 21.3 | Referent | |
Yes | 38.0 | 2.3 | 1.7 to 3.0 |
IV Steroids in past 12 months | |||
No | 22.8 | Referent | |
Yes | 41.1 | 2.4 | 1.5 to 3.7 |
PO Steroids in past 12 months | |||
No | 16.6 | Referent | |
Yes | 37.1 | 3.0 | 2.4 to 3.7 |
Combined family income before taxes ($) | |||
< 20,000 | 27.6 | Referent | |
21,000–40,000 | 18.8 | 0.6 | 0.4 to1.0 |
41,000–60,000 | 24.7 | 0.9 | 0.5 to1.4 |
61,000–80,000 | 26.9 | 0.9 | 0.6 to 1.6 |
> 80,000 | 25.5 | 0.9 | 0.6 to 1.4 |
Prefer not to answer | 21.4 | 0.7 | 0.4 to 1.2 |
Region | |||
Maritimes | 21.0 | Referent | |
Quebec | 28.2 | 1.5 | 0.9 to 2.5 |
Ontario | 23.6 | 1.2 | 0.7 to 1.9 |
Prairies | 22.0 | 1.1 | 0.6 to 1.8 |
West Coast | 22.6 | 1.1 | 0.6 to 2.0 |